Introduction
Diabetic retinopathy is amongst the most feared of the microvascular complications of type 1 and type 2 diabetes mellitus and was until very recently the most common cause of visual loss and blindness in working-aged people. 1, 2 Up to 2010, it was estimated that 35% of people with diabetes worldwide had diabetic retinopathy. 3 As diabetic retinopathy progresses, microvascular changes in the retina can lead to increased permeability, with leakage causing the accumulation of fluid in the macular. The global prevalence of diabetic macular oedema (DMO) in people with diabetes has been estimated as 7% 3 and the condition is the major cause of vision loss in the diabetic population. 4 Several types of therapy are licensed for use in DMO. The Early Treatment Diabetic Retinopathy Study (ETDRS) showed that focal photocoagulation can lead to a reduced loss of vision in people with clinically significant DMO. 5 Subsequently, data from several landmark trials have shown that anti-VEGF therapies can improve vision in people with DMO, [6] [7] [8] [9] and anti-VEGF therapy has become the treatment of choice for the management of DMO. Nevertheless, anti-VEGF therapies are not effective in all people. 10 Dong and colleagues suggest that several cytokines associated with inflammation and angiogenesis contribute to the pathogenesis of diabetic retinopathy. 11 Therefore, a multifactorial approach to the management of diabetic retinopathy could be beneficial. 11 Intravitreal corticosteroids have been shown to be effective in improving visual acuity in DMO [12] [13] [14] and reduce not only the expression of the VEGF gene but also suppress other inflammatory mediators. Intravitreal steroids are therefore potentially useful second-line agents in the management of DMO.
Fluocinolone acetonide (FAc) 190 µg intravitreal implant is licensed in 17 European
countries for the treatment of visual impairment associated with chronic DMO considered insufficiently responsive to available therapies. Two separate randomised clinical trials, Fluocinolone Acetonide in Diabetic Macular Oedema (FAME) A and FAME B, have been conducted to study the clinical effectiveness of FAc intravitreal implant in DMO. 13, 15, 16 These studies recruited people with DMO previously treated with retinal laser therapy, and the combined results of the two trials indicated that the FAc intravitreal implant provided visual benefit for up to three years. 13, 12 Due to its long duration of action, the FAc intravitreal implant needs to be administered less frequently compared with anti-VEGF and other steroid therapies for DMO. 17 However, intravitreal corticosteroids have been shown to be associated with side effects including steroid-induced cataracts and raised intraocular pressure (IOP). [12] [13] [14] The UK National Institute of Health and Care Excellence (NICE) currently recommends that FAc intravitreal implant be used only in eyes with pseudophakic lenses where the DMO has been insufficiently responsive to available therapies. 18 The aim of the Iluvien Clinical Evidence study in the United Kingdom (ICE-UK) was to assess the real-world effectiveness of FAc intravitreal implant for chronic DMO in routine clinical practice. Changes in visual acuity, central foveal thickness (CFT) and IOP were compared between FAc treated and fellow eyes post implant. Whilst randomised trials of DMO-related treatments provide a direct comparison between FAc treated and untreated subjects, here we compared study eyes (first eyes treated with FAc implant) and fellow eyes (the patient's eye not treated with FAc implant, but which may have other standard care) in the same subject since this provides a natural experiment whereby the reference (control) eye is exposed to exactly the same physiological milieu. The low daily release of FAc from the intravitreal implant provides systemic FAc levels that are undetectable in the systemic circulation; 19 therefore the effect of the FAc implant in the study eye affecting the disease in the fellow eye is low. However, unlike randomised controlled trials, the decision as to which eye to treat is likely to be based on a clinical decision. Nevertheless the premise of the study was based on the assumption that there was homogeneity between study and fellow eyes.
Methods

Data Source
This study used a retrospective cohort design. The data source has been described previously. 20 Briefly, data were extracted from patient medical records for a representative cohort of patients registered at 13 participating UK hospitals. Data were pseudonymised and combined into a single dataset. Data included demographics, medical history, implant data, and data from multi-disciplinary and medication reviews at several time points within a designated period.
Ethical approval
The lead clinician and Caldicott Guardian at each centre gave written approval for extraction of anonymised data. The study protocol was approved by the head of research governance at the lead clinical centre. This study was conducted in accordance with the Declaration of Helsinki and the UK Data Protection Act.
Subjects
People with type 1 or type 2 diabetes treated with FAc intravitreal implant for DMO in at least one eye were included in the study. In order to allow for sufficient followup, it was required that the implant be inserted between 1 April 2013 and 15 April 2015 at a participating site as part of the patient's routine care. The period of observation ended on 15 April 2016. A minimum history of 12 months prior to implant was also required, providing information that is not available in randomised controlled trials. People with a history of participating in any interventional study for DMO or with insufficient follow-up were excluded. Reasons for insufficient follow-up included: non-attendance at the clinic and last appointment missing the last appointment post index. Study eyes were defined as the first eye to be treated with FAc implant. Fellow eyes were defined as the eye that received no FAc implant; these could receive other DMO treatments as deemed clinically necessary in routine practice. People whose fellow eye was treated with FAc intravitreal implant within 12 months of the study eye's first treatment were censored at the time of implant, with all remaining subjects followed for 12 months post implant. The index date was defined as the date of the first recorded FAc intravitreal implant into the study eye.
Outcomes
Change in visual acuity, CFT and IOP were investigated at 3, 6 and 12 months post index date in study and fellow eyes. Visual acuity was measured using one of: Early Treatment of Diabetic Retinopathy Study (ETDRS) scores, Snellen fractions or LogMAR scores. All Snellen fractions were converted to approximate ETDRS scores for analysis using the following formula derived by Gregori and colleagues:
approximate ETDRS = 85 + 50 x log (Snellen fraction). All approximate ETDRS scores were rounded to the nearest letter. 21 Snellen fractions were converted to LogMAR scores using the following formula: -1 x log (Snellen fraction). 21 These formulae were rearranged to convert between LogMAR and ETDRS. People who could only detect movement, detect light or count fingers were allocated to 2.3 on the LogMAR scale, the value attributed to people who can count fingers. As this was an observational study, there was no restriction on the optical coherence tomography (OCT) machine type used to measure retinal thickness.
Statistical analysis
Results were compared between study eyes and fellow eyes. Baseline characteristics were displayed for study and fellow eyes overall and by subgroup based on the difference in the mean change in visual acuity between study and fellow eyes at 12 months post implant (> and ≤-0.12 LogMAR units). Baseline characteristics were compared using the paired t-test or Wilcoxon signed rank test for continuous variables, depending on their distribution. Changes in visual acuity, CFT and IOP were compared between study and fellow eyes using the Wilcoxon signed rank test.
Categorical variables were compared using McNemar's test. Due to the observational nature of this study, people did not visit the clinic at set times prior to and following insertion of the FAc intravitreal implant. Therefore last observation carried forward prior to and after implant was implemented in order to impute missing values. 22 Mean change in the four study outcomes on each day following baseline and mean values on each day in the 12 months prior and post index date were calculated using a dataset where missing values had been imputed using linear interpolation. 22 As linear interpolation was not suitable following the last observed value or prior to the first observed value, nearest observation carried forward and backward was used to impute the remaining missing values. 
Results
Data were collected on 311 people, of whom 208 people contributing 208 study eyes and 208 fellow eyes were eligible for inclusion in the study cohort. The number of study subjects excluded has been described previously. 20 
Patient characteristics
Of the 208 people treated with FAc intravitreal implant in the study eye, 128 (62%) were male. Mean age was 68.1 years ( 
Other intraocular interventions
The number of eyes treated with anti-VEGF post FAc implant in the study eye were: 5% of study eyes versus 18% of fellow eyes between 0 and 3 months, 9% of study eyes versus 20% of fellow eyes between 3 to 6 months and 18% of study eyes versus 24% of fellow eyes between 6 and 12 months ( Table 2 ). The number of eyes treated with steroids (other than FAc) post FAc implant in the study eye were: 2% of study eyes versus 1% of fellow eyes between 0 and 3 months, 1% of study eyes versus 1% of fellow eyes between 3 and 6 months and 5% of study eyes versus 1% of fellow eyes between 6 to 12 months. The corresponding figures for macular laser therapy were 2% of study eyes versus 2% of fellow eyes, 3% of study eyes versus 2% of fellow eyes and 5% of study eyes versus 4% of fellow eyes at 0 to 3 months, 3 to 6 months and 6 to 12 months, respectively. A ≥5 letter improvement in ETDRS score was achieved by more study eyes than fellow eyes at each follow-up time point (44% versus 22%, p<0.001, at 3 months; 44% versus 30%, p=0.002, at 6 months; 41% versus 23%, p<0.001, at 12 months post implant, Figure 3 ). More study eyes also achieved a ≥10 letter improvement at 3 months (26% versus 12%, p<0.001), 6 months (30% versus 10%, p<0.001) and 12 months (28% versus 11%, p<0.001) post index date. For a ≥15 letter improvement in ETDRS the corresponding figures for study eyes and fellow eyes were 14% versus 7%, p=0.012 at 3 months; 16% versus 4%, p<0.001 at 6 months; and 18% versus 4%, p<0.001 at 12 months, respectively. At 6 and 12 months post FAc implant, fewer study eyes exhibited a worsening in visual acuity of ≥5, ≥10 and ≥15 letters compared with fellow eyes. However, this only achieved statistical significance for a ≥10 letter worsening in ETDRS letter score at 6 months (10% of study eyes versus 19% of fellow eyes, p=0.014).
Results from the generalised linear mixed multinomial modelling showed that the study eyes were more likely to achieve a ≥5 letter gain in visual acuity and this result was significant at three months (exponential of the coefficient 2.09, 95% CI 1.13-3.88, p=0.019) post implant (Table 3) . Study eyes were not significantly more or less likely to have a worsening of ≥5 letters in visual acuity at 3, 6 and 12 months post implant.
Change in central foveal thickness
In the study eye, CFT fluctuated from 468 µm at -12 months to 445 µm at -4 months before increasing to 471 µm immediately prior to implant (Figure 1 ). Mean CFT then decreased gradually post implant from 407 µm immediately following implant to 358 µm at the end of the 12 months follow-up. For the fellow eye, there was little change in mean CFT in the 12 months before and after implant (CFT 345 µm, 343 µm and 330 µm at -12 months, index date and +12 months, respectively). A difference in the change in CFT was observed between study and fellow eyes between index date and 3 months follow-up (mean -87 µm versus -3 µm, respectively, p<0.001), 6 months follow-up (-90 µm versus -3 µm, respectively, p<0.001) and 12 months follow-up (-113 µm versus -13 µm, respectively, p<0.001, Supplementary Table 2) .
Change in intraocular pressure
Mean IOP was similar and remained relatively stable in both the study and fellow eyes prior to implant (15.7 mmHg and 16.0 mmHg at -12 months and 15.6 mmHg and 16.1 mmHg at implant, respectively, Figure 1 ). Post FAc implant in the study eye, mean IOP increased to 18.8mmHg at the end of the 12 month follow-up period.
Conversely, mean IOP remained stable in the fellow eye (15.9 mmHg at +12 months, Table 2 ).
The number of study versus fellow eyes with an IOP of ≤21 mmHg was 12 (8%) versus 11 (7%) at baseline (N=156 pairs of eye, p=1.000), 26 (18%) versus 19 (13%) at 3 months (N=147, p=0.167), 31 (20%) versus 12 (8%) at 6 months (N=154, p=0.001) and 39 (25%) versus 11 (7%) at 12 months post FAc implant (N=157, p<0.001).
IOP-lowering medicine was initiated in more study eyes than fellow eyes between 0 and 3 months (3% versus 1%), 3 and 6 months (7% versus 1%) and 6 and 12 months (11% versus 4%) post index date.
Discussion
In the study cohort, visual acuity and CFT improved in the 12 months following the insertion of the FAc intravitreal implant when compared with the 12 months prior to implant. Conversely, there was a small but significant increase in IOP in the study eye in the 12 months post FAc implant. For the fellow eye, CFT and IOP remained relatively stable across the 12 month periods prior to and following FAc implant in the study eye. However, there was a small deterioration in visual acuity in the fellow eye post FAc implant. At the end of the 12 month follow-up period, statistically significant improvements in visual acuity and CFT were observed in study eyes treated with FAc intravitreal implant when compared with the fellow eye. However, during the same period, a small statistically significant increase in IOP was observed in study eyes only. More fellow eyes were treated with anti-VEGF therapies in the 12 months post FAc implant when compared with study eyes. However, more study eyes than fellow eyes were treated with steroid therapy between 6 and 12 months post implant. The number of fellow eyes and study eyes receiving macular laser therapy post implant were similar. An important limitation of this study was the difference in visual acuity and CFT between study and fellow eyes prior to FAc implant. However, prior to implant, IOP was similar in study and fellow eyes, suggesting that the comparison between study and fellow eyes is reasonable for this outcome.
To date, the largest randomised controlled trials investigating the effectiveness of FAc have been the FAME studies, where people with DMO previously treated with macular laser therapy were randomised to receive sham injection (n=185), low-dose FAc implant (n=375) and high dose FAc implant (n=393). 12, 13 Campochiaro and colleagues reported that 28.7% of people randomised to 0.2 µg/day FAc implant achieved a ≥15 letter improvement in ETDRS score after three years compared with 18.9% of people randomised to sham injection (p=0.018). 13 The 0.2 µg/day FAc group also received fewer off-protocol treatments for DMO (15.2% compared with 33% for the sham group). 13 In this study, where the fellow eye acted as a control, we found that a ≥15 letter improvement was observed in 18% of study eyes and 4% of fellow eyes after 12 months follow-up (p<0.001). Here, some of the study eyes and fellow eyes also received other DMO treatments as part of their routine care.
However, a higher number of fellow eyes received other treatments for DMO post FAc implant. However, unlike the people included in the FAME studies, whose DMO had previously only been managed with macular laser therapy, 82% of study eyes and 47% of fellow eyes in this study had previously been treated with anti-VEGF injections, and 43% of study eyes and 19% of fellow eyes had been previously treated with steroids (triamcinolone or dexamethasone). Compared with the FAME study, a higher proportion of study eyes and fellow eyes had a pseudophakic lens at baseline (89% of study eyes and 53% of fellow eyes in this study versus 34.6% of those randomised to sham and 37.3% of those eyes randomised to the 0.2 µg/day FAc implant in the FAME study). In addition, people in this study were generally older and there was a higher proportion of people with type 1 diabetes. In a prespecified subgroup analysis, Cunha-Vaz and colleagues reported that a higher percentage of people with chronic DMO gained a 15 letter improvement in visual acuity when compared with those with non-chronic DMO. 23 Although the chronicity of DMO was not collected as part of the ICE-UK study, we undertook a subgroup analysis to determine the baseline characteristics of those people who went on to respond better to FAc implant (difference in mean change in visual acuity between study eye and fellow eye at 12 months ≤-0.12 LogMAR units). We found that people who responded better were in general younger, had worse vision in their study and fellow eye at baseline and were more likely to have been previously treated with at least one steroid injection in the study eye.
The FAMOUS (Fluocinolone in Human Aqueous) RCT, where people were randomised to the 0.2 µg/day implant, reported a mean change in visual acuity of 5.7 letters at 12 months. 24 In a retrospective study carried out by Elaraoud and colleagues, an improvement in visual acuity and CFT was observed in 15 out of 22 eyes treated with FAc intravitreal implant. 25 The subjects included were similar to those included in the ICE-UK study in that all included eyes had a pseudophakic lens and the majority had been previously treated with multiple anti-VEGF and laser therapies. 25 Unlike an RCT where people are randomised to FAc or sham injection, this study had a retrospective observational design whereby the untreated eye acted as a natural control that had been exposed to the same patient and disease factors. However, in 70% of people, the FAc intravitreal implant was inserted into the worse-seeing eye.
At baseline, CFT was greater in the study eye when compared with the fellow eye.
Baseline vision is likely to dictate the improvement or worsening of vision observed in an eye and the difference in visual acuity at baseline between study and fellow eyes. In addition, more fellow eyes received anti-VEGF treatments in the 12 months post FAc implant. These limitations need to be taken into account when interpreting the comparisons between study and fellow eye.
Five cataract operations were observed in study eyes over the follow-up period.
However, the majority of people had a pseudophakic lens in the study eye at the time of implant (89%). In the FAME study, in those with no history of receiving a cataract operation, cataract surgery was reported in 75% of the 0.2 µg/day FAc group and 23% of the sham group after 24 months of follow-up and was the most commonly reported adverse event. 12 At 36 months, these figures were 82% and 51%, respectively. 13 The percentage of eyes with a phakic lens at baseline was higher in the FAME study when compared with ICE-UK (11% versus 65%). 12 More study eyes initiated IOP-lowering medication post index date. IOP-lowering surgery was carried out in one study eye and two fellow eyes within 12 months of implant. However, following insertion of the FAc intravitreal implant, there was a small but statistically significant increase in IOP in study eyes when compared with fellow eyes.
Furthermore, a statistically significant higher percentage of study eyes had an IOP of ≥21 mmHg when compared with fellow eyes. In the FAME study, all included individuals had no prior history of glaucoma. 12 Laser trabeculoplasty and incisional IOP-lowering surgery were reported to have been carried out in 1.3% and 4.8% of the 0.2 µg/day FAc implant group and 0% and 0.5% of the sham group, respectively. 13
Strengths and limitations
The general study limitations have largely been discussed previously. 20 The comparison of study and fellow eyes had statistical limitations. The decision to treat one eye with FAc instead of or before the fellow eye is based on clinical judgment and is not a random event. The study eye often had poorer visual acuity and CFT at baseline compared with the fellow eye. This could have led to confounding by severity. Conversely, worse characteristics at baseline could have potentially led to improved outcomes and therefore favoured the study eye. The FAc implant is licensed for the treatment of DMO considered insufficiently responsive to available therapies. Therefore, when the FAc implant was inserted into the worse-seeing eye, the better-seeing eye could still have been responsive to other DMO treatments.
However, little improvement was observed in the fellow eye over the 12 months before and after index date, and only 18%, 20% and 24% of fellow eyes received anti-VEGF therapy at 0 to 3 months, 3 to 6 months and 6 to 12 months post index date. The UK NICE guidelines recommend that the FAc intravitreal implant be prescribed in eyes with a pseudophakic lens 18 and this may have also influenced the decision as to which eye to treat with FAc. For 37% of patients who received an FAc implant in their worse-seeing eye, the fellow eye was phakic at the time of implant.
For those patients, whose visual acuity was the same or better in the study eye, 31% had a phakic lens in their fellow eye. Collection parameters included DMO type for each eye, but a status of no DMO could not be recorded. Unilateral cases of DMO were reported separately for three study subjects. The level of misclassification of the unilateral and bilateral DMO status is unknown, although 26% patients had no history of receiving any treatment for DMO (laser, intravitreal steroids or anti-VEGF therapy) prior to index date (compared with 3% of study eyes).
Several types of OCT machine were used to measure retinal thickness across the 13 participating ophthalmology centres, and this has been discussed in detail elsewhere. 26 Retinal thickness measurements have been shown to vary depending on machine type, possibly due to variation in the retinal segmentation algorithms used by different OCT machines. 27 However, the same OCT machine type was used to measure retinal thickness in the left and right eye during the same visit.
Due to the low level of systemic absorption, the effect of the FAc implant on the fellow eye is thought to be low. However, bevacizumab has been reported to significantly reduce the level of VEGF in the blood plasma for up to 28 days post injection in people with DMO and age-related macular degeneration. 28, 29 Furthermore, studies have shown that anti-VEGF therapy administered unilaterally can have beneficial effects in the contralateral eye of people with bilateral DMO, 30 age-related diabetic macular degeneration, 31 proliferative diabetic retinopathy, 32 uveitis-related cystoid macular oedema. 33 The potential crossover effect of anti-VEGF therapy on the contralateral (study or fellow) eye is a limitation of the study design.
Conclusion
At the end of the 12 months follow-up period, a statistically significant improvement in visual acuity and CFT and a small but significant increase in intraocular pressure were observed in study eyes treated with FAc intravitreal implant when compared with the fellow eye. Differences in baseline visual acuity and CFT between study and fellow eyes were a limitation of this study. However, considering the study and fellow eyes independently, trends in visual acuity and CFT over the 12 month periods before and after FAc implant highlight the benefit of FAc intravitreal implant in the often poorer study eye. Over the same period, little or no improvement in these outcomes was observed in fellow eyes. 
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